We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Guidance on Postapproval Changes for Synthetics
FDA Issues Guidance on Postapproval Changes for Synthetics
The FDA issued guidance on how sponsors of synthetic drugs should approach post-approval manufacturing process changes — listing examples of low, medium and high risk changes.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor